Black Diamond Therapeutics, Inc. (BDTX)
Nasdaq: BDTX · Biological Products, (No Diagnostic Substances) · Cambridge, MA · filing with the SEC since 2017
Who owns Black Diamond Therapeutics, Inc.
As filed with the SECHolders of 5% or more
2
T. Rowe Price Investment Management, Inc. holds 7% of COMMON STOCK, as its SCHEDULE 13G/A filed Jul 8, 2026 says.
Directors and officers
11
report now, of 25 people on the record since 2020. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
T. Rowe Price Investment Management, Inc.
SCHEDULE 13G/A · filed Jul 8, 2026 · COMMON STOCK
Blackrock, Inc.
SCHEDULE 13G · filed Jul 27, 2026 · Common Stock · 4.5% in Apr 29, 2025
BB Biotech AG
SCHEDULE 13G/A · filed Mar 21, 2025 · Common Stock · reported falling below 5%, from 15.1% in Feb 14, 2025
Vestal Point Capital, LP
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%
What BDTX reports owning in othersstakes of 5% or more, and other ties
1 subsidiary in 1 country, from the list filed with the 10-K filed Mar 12, 2024.
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2023 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.